冠心病患者冠脉循环中血小板功能及前列腺素等的研究
摘要
血小板与血管壁之间相互作用可能是缺血性心脏病发生(发展)的重要因素之一。本研究通过测定患者冠状循环中血小板功能及前列腺素等的变化，从以下几个方面探讨了它们在冠心病不同情况下的作用及抗血小板药物等对它们的影响。
一、冠心病不同临床类型患者冠状循环中血小板功能及前列素等的变化
于47例受试对象，同时采集冠状静脉窦(CS)及升主动脉(AO)血进行血浆及血清血栓烷B_2[TXB_2，血栓烷A_2(TXA_2)的稳定代谢产物]及6-酮前列腺素F_(1α)(前列环素的稳定代谢产物)的测定，部分患者同时进行了血浆cAMP及血小板聚集的测定。结果为，不稳定型心绞痛(UA)患者及急性心肌梗塞(AMI)患者的血浆TXA_2 CS／AO比值明显高于正常对照组及稳定型心绞痛患者(SA)。SA、UA及AMI患者血清TXB_2 CS／AO比值均明显低于正常对照组。UA患者血浆cAMP CS／AO比值明显低于SA及正常对照组。UA患者CS中血小板聚集性明显低于AO中者，而正常对照组中却无明显差别。结果提示，UA及AMI
The interaction between platelet and vessel wall may play an i(?)portant role in the development of ischemia heart disease (IHD). In our research,we measured changes in platelet function and release of prostaglandins in coronary circulation to further study their propable role in different patterns of IHD.
1.Changes in platelet function and prostaglandins levels in coronary circulation in patients with different clinical types ofIHD
Simultaneous coronary sinus (CS) and ascending-aorta (AO) blood samples were obtained from 47 patients for measurement of plasma and serum thromboxane B_2 [TXB_2, a stable metabolite of thromboxane A_2 (IXA_2)] and of 6-keto-prostaglandin F_1a [ 6-keto-PGF_1a , a stable netabolite of prostacyclin I_2 (PGI_2)]. Samples from some of these patients were also tested for platelet aggregation and plasma. cAMP. The results showed (1) patients with unstable angina pectoris (UA) and acute myocardiol infarction (AMI) had higher plasma TXB_2 CS/AO ratios (1.66±0.20 and 2.32 ±0.47, respectively) than patients with stable angina (SA) and control subjects (1.04±0.17 and 1.00±0.06, respectively) (p<0.05); (2) serum TXB_2 CS/AO ratios in patients with SA, UA or AMI were significantly lower when compared with control subjects; (3)plasma cAMP CS/AO ratios were lower in patients with UA than those in patients with SA or control subjects; (4)platelet aggregation in CS blood significantly decreased than that in A0 blood in patients with UA,but there was no difference in platelet function between A0 and CS in control subjects; (5) no significant differences
一、冠心病不同临床类型患者冠状循环中血小板功能及前列素等的变化
于47例受试对象，同时采集冠状静脉窦(CS)及升主动脉(AO)血进行血浆及血清血栓烷B_2[TXB_2，血栓烷A_2(TXA_2)的稳定代谢产物]及6-酮前列腺素F_(1α)(前列环素的稳定代谢产物)的测定，部分患者同时进行了血浆cAMP及血小板聚集的测定。结果为，不稳定型心绞痛(UA)患者及急性心肌梗塞(AMI)患者的血浆TXA_2 CS／AO比值明显高于正常对照组及稳定型心绞痛患者(SA)。SA、UA及AMI患者血清TXB_2 CS／AO比值均明显低于正常对照组。UA患者血浆cAMP CS／AO比值明显低于SA及正常对照组。UA患者CS中血小板聚集性明显低于AO中者，而正常对照组中却无明显差别。结果提示，UA及AMI
The interaction between platelet and vessel wall may play an i(?)portant role in the development of ischemia heart disease (IHD). In our research,we measured changes in platelet function and release of prostaglandins in coronary circulation to further study their propable role in different patterns of IHD.
1.Changes in platelet function and prostaglandins levels in coronary circulation in patients with different clinical types ofIHD
Simultaneous coronary sinus (CS) and ascending-aorta (AO) blood samples were obtained from 47 patients for measurement of plasma and serum thromboxane B_2 [TXB_2, a stable metabolite of thromboxane A_2 (IXA_2)] and of 6-keto-prostaglandin F_1a [ 6-keto-PGF_1a , a stable netabolite of prostacyclin I_2 (PGI_2)]. Samples from some of these patients were also tested for platelet aggregation and plasma. cAMP. The results showed (1) patients with unstable angina pectoris (UA) and acute myocardiol infarction (AMI) had higher plasma TXB_2 CS/AO ratios (1.66±0.20 and 2.32 ±0.47, respectively) than patients with stable angina (SA) and control subjects (1.04±0.17 and 1.00±0.06, respectively) (p<0.05); (2) serum TXB_2 CS/AO ratios in patients with SA, UA or AMI were significantly lower when compared with control subjects; (3)plasma cAMP CS/AO ratios were lower in patients with UA than those in patients with SA or control subjects; (4)platelet aggregation in CS blood significantly decreased than that in A0 blood in patients with UA,but there was no difference in platelet function between A0 and CS in control subjects; (5) no significant differences
引文
1. Abrams J, et al: Angina pectoris: Mechanisms, diagnosis, and therapy. Cardiology Clinics. 1991, 9(1).
2. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Sociatg and Federation of Cardiology/World Heart Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979, 59: 607.
3. Dehmer D J, et al: A Ney technique for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 1986, 12: 426.
4. Born G V R: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 6: 927.
5. Hjemdahl P, et al: Effects of stress and β-blockade on platelet function. Circulation 1991, 84(Suppl Ⅵ): Ⅵ-44-Ⅵ-61.
6. Mehta J, et al: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3.Role of tachycardia stress and propranolol. Circulation, 1978, 58: 881.
7. Moncada S, Vane J R: Arachidonic acid metabolites and the interactions between platelets and blood vessel Walls. N Engl J Med 1979, 300: 1142.
8. Hamberg M, et al: Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Aced Sci USA 1975, 72: 299.
9. Moncada S, et al: An enzyme isolated from arteries transform pros-taglandin endoperoxides to an unstable Substance that inhibits platelet aggregation. Nature 1976, 263: 663.
10. Moncada S. Vane J R: Pharmacology and enologenous roles of prosta-glandin eadoperoxides, thromboxane A_2, and prostacyclin. Pharmacol Rev. 1979, 30: 293-331.
11. Fitzpatrich. F A, et al: A radioimmunoassay for thromboxane B_2. Anal Biochem. 1977, 82: 1.12. Sors H, et al: Analytical methods for thromboxane B_2 measurement and validation of radioimmunoassay by gas Liquid chromtography mass-spectrometry. Prostaglandins. 1978, 16: 277.
13. Viinikka L, Ylikorkala O: Measurement of thromboxane B_2 in human plasma or serum by radioimmunoassay. Prostaglandins. 1980, 20: 759.
14. Parry M J, et al: Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leucocytes in angina patients and healthy volunteers. Lancet 1982, 2: 164.
15. Mehta J, et al: Platelet function and biosgnthesis of PGI_2 and TXA_2 in Whole blood after aspirin administration in huron Subjects. JACC 1984, 4: 806-11.
16. Maseri A, et al: Mechanisms of Blood-vessel wall interaction. Circulation. 1990, 81 (suppl Ⅰ): Ⅰ-40-Ⅰ-41.
17. Yui Y, et al: Intravenous infusion of a selective inhibitor of TXA_2 syntbetase in man: Influence on TXB_2 and 6-Keto-PGF_(1α) levels and platelet aggregation. Circulation 1984, 70: 599.
18．许澍淮：环核苷酸与血小板功能，生理科学进展．1992，23：318．
19. Thaulow E, et al: Pacing induced angina and platetet reactivity. Scand J Clin Lab Invest 1982, 42: 607-611.
20. Robertson R M, et al: Platelet aggregations in peripheral and coronary sinus blood in patients with spontaneous coronary-Artey spasm Lancet 1980, 2: 829.
21．李振甲主编：实用放射免疫学，科学技术文献出版社．1989，198-221．
22. Patrano C, et al: Low dose aspirin and inhibition of thromboxane B_2 production in healthy subjects. Thromb Rcs 1980, 17: 317-27.
23. Gilmn A G: A protein binding assay for adenosine 3',5'-cyclic mnophosphate. Proc Natl Acad Sci USA 1970, 67: 305.
24. Hirsh P D, et al: Influence of blood sampling site and technique on thromboxane concentrations in patients with ischelic heart disease. Am Heart J 1982, 104: 234.
25. Gershlick AH: Are there markers of the blood-vessel wall interaction??and of thrombus formation that can be used clinically? Circulation 1990, 81 (Suppl Ⅰ): Ⅰ-28-34.
26. Hirsh PD, et al: Release of prostaglandins and Thromboxane into the coronary circulatien in patients with ischemic Heart disease. N Engl J Med 1981, 304: 685-91.
27. Thaulow E: Effects induced on blood. platelet in ischemic and Nonischemic myocardium. Am J Cardiol 1983, 52: 466-469.
28．吴其夏：血小板激活的放大和去敏感．生理科学进展 1992，23：199-203．
29. Neri Serneri G G, et al: Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina. Thromb Res 1987, 46: 303-316.
30. Fitzgerald D J, et al: Platelet activation in unstable coronary disease. N Engl J Med 1986, 315: 983-9.
31. Herren A G: Platelet activation and aggregation: Rationale for combining antithrombotic drugs. In: Herman A G ed. Antithrombotics. Dordrecht: Kluwer Academic Publishers 1991, 1-26.
32. Folts J D: An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation, 1991, 83(Suppl Ⅳ): Ⅳ-3.
33. Willerson J T, et al: Specific platelet mediators and unstable coronary artery lesions, Ciculation 1989, 82: 198.
34. Fuster V, Badimon L, Badimon JJ, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326: 242-250.
35．张夏英，等．环磷酸腺苷测定对判断急性心肌梗塞患者预后价值的探讨．中华内科杂志 1979，18：109．
36. Thandroyen FT, Muntz KH, Buja LM, et al: Alteration in β-adrenergic receptor, adenglate cyclase, and cyclic AMP concentrations during acute myocardial ischemia and reperfusion. Circulation. 1990, 82 (Suppl Ⅱ): Ⅱ-30-Ⅱ-37.
37. Levin D C, Fallon J T: Significance of the angiographic morphology??of localized coronary stensis: Histopathologic correlation. Circulation 1982, 66: 316.
38. Ambrose J A, Winters S L, Stern A, et al: Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985,5:609.
39. Lo Y S, Cutler J, Blake K, et al: Angiographic coronary morphology in survivors of cardiac arrest. Am Heart J 1988, 115: 781.
40. Ip J H, Fuster V, Israel D, et al: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. JACC 1991, 17: 77B-88B.
41. Steele P M, Chesebro J H, Stanson A W, et al: Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Cir Res 1985, 57:105-112.
42. Lassila R, Badimon J J, Vallabhajosula S, et al: Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: Effects of different stenosis on thrombus growth. Arteriosclerosis 1990, 10: 306-15.
43. Lam JYT, Chesebro JH, Steele PM, et al: Antithrombotic therapy for deep arterial injury by angioplasty: Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991, 84: 814-820.
44．高润霖，陈在嘉，姚康宝，等：经皮冠状动脉腔内成形术13例报告．中国循环杂志 1988，3：230．
45. Bush L R, et al: Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984, 69:1161.
46. Austin J, et al: Thromboxane synthetase inhibition reduces ventricular irrtability after coronary occlusion and reperfusion. Am Heart J 1988, 115: 505.
47. Schwartz L, Bourassa MG, Lesperance J, et al: Aspirin and dipyridmole in the prevention of restenosis after PTCA. N Engl J Med 1988, 318:??1714-9.
48. Serruys PW, Rutsch W, Heyhdrichx GR, et al: Prevention of restenosis after FTCA with thromboxane Az-receptor blockade: A radomized, double-blind, placebo-controlled trial. Circulation 1991,84:1568-80.
49. Becket R C: Thrombin antagonists and antiplatelet agents. Am J Cardiol 1992,69:39A.
50．高树伟，陈在嘉，陶寿淇：小剂量阿司匹林对冠心病患者血小板聚集和前列环素-血栓素A_2平衡的影响．中华内科杂志 1987，26：209-212．
51. Mehta P, et al: Effects of aspirin in arterial thrombosis: Why don't animals behave the way humans do? J Am Coll Cardiol 1993,21:511-3.
52. Schror K: Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequence for platelet-vessel wall interaction. In: Herman AG. ed. Antithrombotics. Dordrecht. Kluwer Academic publishers. 1991.139-158.
53. Mehta JL, Conti CR: Aspirin in myocardial ischemia: Why, when, and how much? Clin Cardiol 1989,12:179-184.
54. Decaterina R, et al: Selective inhibition of thromboxane-related platelet function by low dose aspirin in patients after myocardial infarction, Am J Cardiol 1985,55:589.
55. Kyrle P A, et al: Inhibition of prostacyclin and thromboxane A_2 generation by low-dose aspirin at the site of plug formation in man in vitro. Circulation 1987,75:1025.
56. Vejar M, et al: Comparision of low-dose aspirin and coronary vasodilators in acute unstale angina. Circulation 1990, 81(Suppl Ⅰ): Ⅰ-4-Ⅰ-11.
57. Fitzgerald G A, et al: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983,71:676-688.
59. Altman J D, et al: Effect of aspirin on coronary collateral blood flow. Circulation 1993,87;583-89.
60. Stein B, et al: Platelet inhibitor agent in cardiovascular disease:??An update. J Am Coll Cardiol 1989,14:813.
61. Ashton JH, et al: Serotonin S_2 and thromboxane A_2/prostaglandin H_2 receptor blockade provide protection against epiephrine-induced cyclic flow variations in serverely narrowed canine coronary arteries. J Am Coll Cardiol 1989, 13:775.
62. Serruys P W, et al: Evaluation of ketanserin in the prevention of restenosis after PTCA: A muticenter randomized double-blind placebocontrolled trial. Circulation 1993,88:1588-1601.
63. Fuster V, et al: Clinical-pathological correlation of coronary disease progression and regression. Circulation 1992, 86(Suppl Ⅲ): Ⅲ-1-11.
64. Granstrom E: Aspects on measurement of prostaglndins and thromboxanes. Am Clin Biochem 1979,16:6.
65. Sinzinger H, Feigl W, Silberbauer K: Prostacyclin generation in atherosclerotic arteries. Lancet 1979,2:469.
66. Fitzgerald GA, et al: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet-activation. N Engl J Med 1984, 310:1065-81. Gershliek AH: Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? Circulation 1990, 81(Suppl Ⅰ): Ⅰ-28-34.
2. Hjemdahl P, et al: Effects of stress and β-blockade on platelet function. Circulation 1991, 84(Suppl Ⅵ): Ⅵ-44-Ⅵ-61.
3. Mehta J, et al: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3.Role of tachycardia stress and propranolol. Circulation, 1978, 58:881.
4. Hirsh P D, et al: Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J 1982,104:234.
5. Montalescot G, et al: Evaluation of t hromboxane production and complement activation during myocardial ischamia in patients with angina pectoris. Circulation 1991, 84:2054-62.
6. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962,6:927.
7. Diodati J, et al: Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarcton. Am J cardiol 1990,66:683.
8. Moncada S, Vane JR: Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979, 300: 1142.
9. Hamberg M, et al: Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975, 72:299.
10. Viinikka L, et al: Measurement of thromboxane B_2 in human plasma or serum by radioimmunoassay. Prostaglandins 1980,20:759.
11. Patrano C, et al: Low dose aapirin and inhibition of thrombexane B_2 production in healthy subjects. Thromb Res 1980, 17:317-27.12. McGill D, et al: Platelet function and exercise induced myocardial ischemia in coronary heart disease patients. Thromb Res 1989,56: 147.
13. Patrono C: Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990, 81(Suppl Ⅰ): 12-15.
14. Canmeron H A, et al: Platelet size in myocardial infarction. Br Med J 1983,287:449-51.
15. Nerman A G: Platelet activation and aggregation: Rationale for combining antithrombotic drugs. In: Herman AG, ed. Antithrombotics Dordrecht: Kluwer Academic publishers. 1991:1-26.
16．许澍淮：环核苷酸与血小板功能．生理科学进展 1992，23：318．
17. Vaughan DE: Pathophysiology of unstable angina: Other consideration. In: Rutherford JD. ed. Unstable angina. New York: Marcel Dekker.INC. 1992:69-83.
18. Moncada S,et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663.
19. Sors H, et al: Analytical methods for thromboxane B_2 measurement and validation of radioimmunoassay by gas liquid chromatography mass-spectrometry. Prostaglandin. 1978,16:277.
20. Parry M J, et al: Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leucocytes in angina patients and healthy volunteers. Lancet 1982,2:164.
21. Mehta J, et al: Platelet function and biosynthesis of PGI_2 and TXB_2 in whole blood after aspirin administration in human subjects. JACC 1984,4:806-11.
22. Dehmer G J, et al: A new technique for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 1986,12:426.
23. Mehta J, et al: Role Of blood platelet and prostaglandins in coronary artery disease. Am J Cardiol 1981,48:366.
24. Bugiardini R, et al: Evaluation of the effects of catheter sampling??for the study of platelet behavior in the pumonary and coronary. Circulation. Am Heart J 1984,108:255.
25. Nichols A B, et al: Effect of heparin bonding on catheter-induced firin formation and platelet activation. Circulation 1984,70:843.
26. Tate D A, et al: Platelet activation during coronary intervention detected by measurement of platelet-derived microparticles and glycoprotein Ⅱb/Ⅲa expression on platelets in coronary sinus blood. JACC 1993, 21: 77A.
27. Watts SE, et al: Storage of platelets for tests of platelet function: Effects of PH on platelet aggregation and liberation of β-thromboglobulin. Thromb Res 1983,29:343-53.
28. Mehta P, et al: Platelet aggregation across the myocardial vascular bed in man. I.Normal versus diseased coronary arteries. Throm Res 1979, 14:423.
29. Ross R: The pathogenesis of atherosclerosis: An update. N Engl J Med 1986.314:488-499.
30. Dinerman JL. Mehta JL: Endothelial, platelet and leukcyte interactions in ischemic heart disease: Insights into potential mechanism and their clinical relevance. J Am Coll Cardial 1990.16:207-22.
31. Badimon JJ, Fuster V, Chesebro JH et al: Coronary atherosclerosis: A multifactorial disease. Circulatlon. 1993, 87(Suppl Ⅱ): Ⅱ-3-16.
32. Mehta J: Prostaglandin: regulatory role in cardiovascular system and implications in ischemia heart disease. Int J Cardiol 1983,4:246.
33. Fox KAA: Thrombolysis: Adjuvant therapy and the role of complement. Eur Heart J 1990, 11(Suppl F)34-42.
34. Neri Serneri GG, et al: Txb2 production by human arteries and viens Prostaglandins 1983, 25:753.
35. Schror K: Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischemia, Eur Heart J. 1990, 11 (Suppl.B)27-34.
36. Smith E F, Lefer A M, and Nicolau K C: Mechanism of coronary??vasoconstriction by carbocycl ic thromboxane A_2. Am J Physiol. 1981, 240: H493-H497.
37. Mehta J, Nichols W, Mehta P, et al: Thromboxane and prostacyclin in systemic and coronary vascular beds following endoperoxide analogue infusion. Am J Cardiol. 1982,49:1014.
38. Flores N A, Sheridan D J: Platelet mediated alteration in cardiac cellular electrophysiology during normal perfusion and myocardial ischemia. Br Heart J 1991,66:54.
39. Parratt J R and Wainwright C L: Ventricular arrhythmias induced by local injections of vasoconstrictors following coronary artery occlusion. Br J Pharmacol 1986,88:397p.
40. Mehta J, Mehta P, Horalek C:The significance of platelet-vessel wall prostaglandin equilibrium during exercise-induced stress. Am Heart J 1983,105:895.
41. Mehta J, Mehta P et al: Thromboxane release in coronary artery disease: Spontaneous versus pacing-induced angina. Am Heart J 1984,107:286.
42. Cortellaro M, et al: Transcoronary platelat thromboxane A_2 formation without platelet trapping in patients with coronary stenosis—Effect of sulphinpyrozone treatment. Thromb Haemost 1983,50(4):857-859.
43. Tada M, et al: Elevation of thromboxane B_2 levels in patients with classic and variant angina pectoris. Circulation 1981,64:1107.
44. Montalescol G, et al: Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 1991,64:2054-2062.
45. Diodati J G, et al: Platelet activation across the coronary bed in patients with coronary artery disease. J Am Coll Cardiol 1991,17: 321A.
46. Nichols A B, et al: Effect of pacing-induced myocardial ischemia on platelet activation and fibrin formation in the coronary. circulation. J Am Coll Cardiol 1987,10:40-45.
47. Wennmalm A, et al: Excretion of thromboxane A_2 and prostacyclin??metabolites before and after exercise testing in patients with and without signs of ischemic heart disease. Circulation 1990,82: 1737-1743.
48. Fuster V, Badimon L, Badimon J J, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250.
49. Zahavi M, Zahavi J, et al: Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. Thromb and Haemost 1989, 62: 840-845.
50. Theroux P, et al: Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987,75:156-162.
51. Neri Serneri G G, et al: Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina. Thromb Res 1987,46:303-316.
52. Fitzgerald D J, Roy L, Catella C, et al: Platelet activation in unstable coronary disease, N Engl J Med 1986,315:983-9.
53. Meri Serneri G G, et al: Abnormal cardiocoronary thromboxane A_2 production in patients with unstable angina. Am Heart J 1985, 109:732-38.
54. Mikhailidis D J P, et al: Platelet function in patients admitted with diagnosis of myocardiol infarction. Angiology 1987,38:36.
55. Tada M, et al: Augmentod thromboxane A_2 generation and efficacy of its blockade in acute myocardial infarction. Int J cardiol 1985, 8: 301-312.
56. Henriksson P, et al: In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986,55:543-8.
57. Mcdaniel H G, et al: Platelet function abnormalites in response to arachidonic acid in the acute phase of myocardial infarction. Am J cardiol 1983,52:965.
58. Takatsu Y, Yui Y, Hattori R, et al: Platelet aggregation and plasma??thromboxane B_2 in acute myocardial infarction, J moll Cell Cardiol 1985, 17(Suppl 1)1-89.
59. Yamazaki H, et al: Thromboxane A2 synthesizing activity of platelet in coronary artery disease. Jap Cir J 1987,51:451.
60. Takatsu Y et al: Platelet aggregation and thromboxane B_2 release in patients with AMI-Their relation to coronary patency. Jpn Cir J 1988,52:314.
61. Gallino A, et al: Fibrin formation and platelet aggregation in patients with severe coronary artery disease: Relationship with the degree of myocardial ischemia. Circulation 1985,72:27-30.
62. Dalal J J et al: Platelet counts and aggregation in coronary artery disease. Eur Heart J 1982,3:107-113.
63. Robertson RM, et al: Platelet aggrogation in peripheral and coronary sinus blood in patients with spontaneous coronary-artery spasm. Lancet 1980,2:829.
64. Numano F, Aizawa T, Nomura S, et al: Coronary spasma, prostaglandin and and HLA factors. Jap Cir J 1985, 49:119-27.
65. Neri Serneri G G, et al: Reduced prostacyclin production in patiens with different manifestation of ischemia heart disease. Am J Cardiol 1982,49:1146.
66. Fitzgerald GA, et al: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984,310:1065-8.
67. Neri Serneri G G, et al: Impaired cardiac PGI_2 and PGE_2 biosynthesis in patients with angina pectoris. Am Heart J 1986,112:472.
68. Neri Serneri G G, et al: Defective coronary prostaglandin modulation in anginal patients. Am Heart J 1990,120:12.
69. Schror K: Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequences for platelet-vessel wall interactions. In: Herman AGed. Antithrombotics. Dordrecht: Kluwer Academic publishers 1991,139-158.70. Serruys PW, Rutsch W. Heyndrickx G R, et al: Prevention of restenosis after PTCA with thromboxane A_2-receptor biockade. Circulation 1991, 84:1568-1580.
71. Mehta JL, Conti CR: Aspirin in myocardial ischemia: Why, when, and how much? Clin Cardiol 1989,12:179-184.
72. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988,2:349.
73. The Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1988,318:262.
74. Peto R, Gray R, Collins R, et al: A randomised trial of the effects of prophylactic daily aspirin among male British doctors. Br Med J 1988, 296:313.
75. Decaterina R, Giannessi D, Bernini W, et al: Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985,5:589.
76. Altman J D, Dulas D, Pavek T, et al: Effect of aspirin on coronary collateral blood flow. Circulation 1993, 87:583-589.
77. Forman MB, Virmani R, Puett DW: Mechanisms and therapy of myocardial reperfusion injury. Circulation 1990, 81(Suppl Ⅳ): Ⅳ-69-Ⅳ-78.
78. Laws KH et al: Kinetics and imaging of indium-111-labeled platelets in experimental myocardiol infarction. Circulation 1983,67:110.
79. Ruf W, et al: Platelet trapping in myocardial infarct in baboons: Therapeutic effect of aspirin. Am J cardiol 1980,46:405.
80. Tomoda H, et al: Development of experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). Am Heart J 1986,112:696.
81. Austin J, et al:Thromboxane synthetase inhibitor reduces ventricular irrtability after coronary occulusion and reperfusion. Am Heart J 1988,115:505.
82. Grover G J, and Schumacher W: Effect of the thromboxane receptor??antagonist SQ29548 on myocardial infarct size in dogs. J Cardiovasc Pharmacol. 1988,11:29-35.
83. Tsuchida A, Miuka T. Ogawa T, et al: Inhibition of thromboxane A_2 synthetase failed to limit myocardial infarct size in a rabbit ischemia reperfusion model.Jpn Cir J 1991,55:174.
84. Sato N, Endo T, Kiuchi K, et al: Effect of a thromboxane synthetase inhibitor, Y-20811 on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occulusion and reperfusion in dogs. J Cardiovasc pharmacol 1993,21:353-361.
85. Fitzgerald D J, Vright F,FitzGerald G A, et al: Increased thromboxane biosynthesis during coronary thrombolysis: Evidence that platelet activation and thromboxane A_2 modulate the response to tissue-type plaminogen activity in vivo. Cir Res 1989,65:83-94.
86. Rebuzzi AG, Natale A, Bianchi C, et al: Importance of reperfusion on thromboxane A_2 metablite excretion after thrombolysis. Am Heart J 1992.123:560.
87. Schwartz L, Bourassa MG, Lesperance J, et al: Aspirin and dipyridamde in the prevention of restenosis after PTCA. N Engl J Med 1988,318: 1714-19.
88. Ip JH, Fuster V, Iserael D, et al: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J An Coll Cardiol 1991, 17:77B-88B.
89. Badimon L, Badimon JJ, Zuritto VT, et al: Platelet thrombus formation on collagen type Ⅰ: A model of deep vessel injury: Influence of blood rheology, von Willebrand factor and blood coagulation. Circulation 1988, 78:1431-42.
90. Steele PM, Chesebro JH, Stanson AW, et al: Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Cir Res 1985, 57:105-112.
91. Vilentz JR, Sanborn TA, Haudenschild CC, et al: Platelet accumulation in experimental angioplasty: Time course and relation to vascular??injury. Circulation 1987, 75:636-642.
92. Foxon D P, Balelli L A, Sanborn T, et al: The effect of antiplatelet therarpy on platelet accumulation after experimental angioplasty in the rabbit iliac model. Int J Cardiol 1992, 36:41-47.
93. Sassover M A, Abela G S,Koch J M, et al: Angioscopic evaluation of periprocedural and postprocedural abrupt closure after percutaneous coronary angioplasty. Am Heart J 1993,126:444-450.
94. Nobuyoshi M, Kimura T, Ohishi H, et al: Restenosis after PTCA: pathologic observation in 20 patients. J Am Coll Cardiol 1991, 17:433-9.
95. Agrawal SK, Rustagi PK, Quarles LA, et al: Platelet activation during PTCA-is current antithrombotic therapy sufficiently effective? J Am Coll Cardiol 1992 19(Suppl A)108A.
96. Nante S, et al: The effect of percutaneous transluninal coronary angioplasty on syntheses of thromboxane A_2 and prostacyclin in coronary circulation. J Moll Cell Cardiol 1985, 17(Suppl 1)1:90.
97. Peterson MB, et al: THromboxane release during PTCA. Am Heart J 1986,111:1-6.
98. Schwartz L, et al: The role of antiplatelet agents in modifying the extent of restenosis following PTCA: Am Heart J 1990, 119:232.
2. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Sociatg and Federation of Cardiology/World Heart Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979, 59: 607.
3. Dehmer D J, et al: A Ney technique for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 1986, 12: 426.
4. Born G V R: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 6: 927.
5. Hjemdahl P, et al: Effects of stress and β-blockade on platelet function. Circulation 1991, 84(Suppl Ⅵ): Ⅵ-44-Ⅵ-61.
6. Mehta J, et al: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3.Role of tachycardia stress and propranolol. Circulation, 1978, 58: 881.
7. Moncada S, Vane J R: Arachidonic acid metabolites and the interactions between platelets and blood vessel Walls. N Engl J Med 1979, 300: 1142.
8. Hamberg M, et al: Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Aced Sci USA 1975, 72: 299.
9. Moncada S, et al: An enzyme isolated from arteries transform pros-taglandin endoperoxides to an unstable Substance that inhibits platelet aggregation. Nature 1976, 263: 663.
10. Moncada S. Vane J R: Pharmacology and enologenous roles of prosta-glandin eadoperoxides, thromboxane A_2, and prostacyclin. Pharmacol Rev. 1979, 30: 293-331.
11. Fitzpatrich. F A, et al: A radioimmunoassay for thromboxane B_2. Anal Biochem. 1977, 82: 1.12. Sors H, et al: Analytical methods for thromboxane B_2 measurement and validation of radioimmunoassay by gas Liquid chromtography mass-spectrometry. Prostaglandins. 1978, 16: 277.
13. Viinikka L, Ylikorkala O: Measurement of thromboxane B_2 in human plasma or serum by radioimmunoassay. Prostaglandins. 1980, 20: 759.
14. Parry M J, et al: Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leucocytes in angina patients and healthy volunteers. Lancet 1982, 2: 164.
15. Mehta J, et al: Platelet function and biosgnthesis of PGI_2 and TXA_2 in Whole blood after aspirin administration in huron Subjects. JACC 1984, 4: 806-11.
16. Maseri A, et al: Mechanisms of Blood-vessel wall interaction. Circulation. 1990, 81 (suppl Ⅰ): Ⅰ-40-Ⅰ-41.
17. Yui Y, et al: Intravenous infusion of a selective inhibitor of TXA_2 syntbetase in man: Influence on TXB_2 and 6-Keto-PGF_(1α) levels and platelet aggregation. Circulation 1984, 70: 599.
18．许澍淮：环核苷酸与血小板功能，生理科学进展．1992，23：318．
19. Thaulow E, et al: Pacing induced angina and platetet reactivity. Scand J Clin Lab Invest 1982, 42: 607-611.
20. Robertson R M, et al: Platelet aggregations in peripheral and coronary sinus blood in patients with spontaneous coronary-Artey spasm Lancet 1980, 2: 829.
21．李振甲主编：实用放射免疫学，科学技术文献出版社．1989，198-221．
22. Patrano C, et al: Low dose aspirin and inhibition of thromboxane B_2 production in healthy subjects. Thromb Rcs 1980, 17: 317-27.
23. Gilmn A G: A protein binding assay for adenosine 3',5'-cyclic mnophosphate. Proc Natl Acad Sci USA 1970, 67: 305.
24. Hirsh P D, et al: Influence of blood sampling site and technique on thromboxane concentrations in patients with ischelic heart disease. Am Heart J 1982, 104: 234.
25. Gershlick AH: Are there markers of the blood-vessel wall interaction??and of thrombus formation that can be used clinically? Circulation 1990, 81 (Suppl Ⅰ): Ⅰ-28-34.
26. Hirsh PD, et al: Release of prostaglandins and Thromboxane into the coronary circulatien in patients with ischemic Heart disease. N Engl J Med 1981, 304: 685-91.
27. Thaulow E: Effects induced on blood. platelet in ischemic and Nonischemic myocardium. Am J Cardiol 1983, 52: 466-469.
28．吴其夏：血小板激活的放大和去敏感．生理科学进展 1992，23：199-203．
29. Neri Serneri G G, et al: Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina. Thromb Res 1987, 46: 303-316.
30. Fitzgerald D J, et al: Platelet activation in unstable coronary disease. N Engl J Med 1986, 315: 983-9.
31. Herren A G: Platelet activation and aggregation: Rationale for combining antithrombotic drugs. In: Herman A G ed. Antithrombotics. Dordrecht: Kluwer Academic Publishers 1991, 1-26.
32. Folts J D: An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation, 1991, 83(Suppl Ⅳ): Ⅳ-3.
33. Willerson J T, et al: Specific platelet mediators and unstable coronary artery lesions, Ciculation 1989, 82: 198.
34. Fuster V, Badimon L, Badimon JJ, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326: 242-250.
35．张夏英，等．环磷酸腺苷测定对判断急性心肌梗塞患者预后价值的探讨．中华内科杂志 1979，18：109．
36. Thandroyen FT, Muntz KH, Buja LM, et al: Alteration in β-adrenergic receptor, adenglate cyclase, and cyclic AMP concentrations during acute myocardial ischemia and reperfusion. Circulation. 1990, 82 (Suppl Ⅱ): Ⅱ-30-Ⅱ-37.
37. Levin D C, Fallon J T: Significance of the angiographic morphology??of localized coronary stensis: Histopathologic correlation. Circulation 1982, 66: 316.
38. Ambrose J A, Winters S L, Stern A, et al: Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985,5:609.
39. Lo Y S, Cutler J, Blake K, et al: Angiographic coronary morphology in survivors of cardiac arrest. Am Heart J 1988, 115: 781.
40. Ip J H, Fuster V, Israel D, et al: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. JACC 1991, 17: 77B-88B.
41. Steele P M, Chesebro J H, Stanson A W, et al: Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Cir Res 1985, 57:105-112.
42. Lassila R, Badimon J J, Vallabhajosula S, et al: Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: Effects of different stenosis on thrombus growth. Arteriosclerosis 1990, 10: 306-15.
43. Lam JYT, Chesebro JH, Steele PM, et al: Antithrombotic therapy for deep arterial injury by angioplasty: Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991, 84: 814-820.
44．高润霖，陈在嘉，姚康宝，等：经皮冠状动脉腔内成形术13例报告．中国循环杂志 1988，3：230．
45. Bush L R, et al: Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984, 69:1161.
46. Austin J, et al: Thromboxane synthetase inhibition reduces ventricular irrtability after coronary occlusion and reperfusion. Am Heart J 1988, 115: 505.
47. Schwartz L, Bourassa MG, Lesperance J, et al: Aspirin and dipyridmole in the prevention of restenosis after PTCA. N Engl J Med 1988, 318:??1714-9.
48. Serruys PW, Rutsch W, Heyhdrichx GR, et al: Prevention of restenosis after FTCA with thromboxane Az-receptor blockade: A radomized, double-blind, placebo-controlled trial. Circulation 1991,84:1568-80.
49. Becket R C: Thrombin antagonists and antiplatelet agents. Am J Cardiol 1992,69:39A.
50．高树伟，陈在嘉，陶寿淇：小剂量阿司匹林对冠心病患者血小板聚集和前列环素-血栓素A_2平衡的影响．中华内科杂志 1987，26：209-212．
51. Mehta P, et al: Effects of aspirin in arterial thrombosis: Why don't animals behave the way humans do? J Am Coll Cardiol 1993,21:511-3.
52. Schror K: Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequence for platelet-vessel wall interaction. In: Herman AG. ed. Antithrombotics. Dordrecht. Kluwer Academic publishers. 1991.139-158.
53. Mehta JL, Conti CR: Aspirin in myocardial ischemia: Why, when, and how much? Clin Cardiol 1989,12:179-184.
54. Decaterina R, et al: Selective inhibition of thromboxane-related platelet function by low dose aspirin in patients after myocardial infarction, Am J Cardiol 1985,55:589.
55. Kyrle P A, et al: Inhibition of prostacyclin and thromboxane A_2 generation by low-dose aspirin at the site of plug formation in man in vitro. Circulation 1987,75:1025.
56. Vejar M, et al: Comparision of low-dose aspirin and coronary vasodilators in acute unstale angina. Circulation 1990, 81(Suppl Ⅰ): Ⅰ-4-Ⅰ-11.
57. Fitzgerald G A, et al: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983,71:676-688.
59. Altman J D, et al: Effect of aspirin on coronary collateral blood flow. Circulation 1993,87;583-89.
60. Stein B, et al: Platelet inhibitor agent in cardiovascular disease:??An update. J Am Coll Cardiol 1989,14:813.
61. Ashton JH, et al: Serotonin S_2 and thromboxane A_2/prostaglandin H_2 receptor blockade provide protection against epiephrine-induced cyclic flow variations in serverely narrowed canine coronary arteries. J Am Coll Cardiol 1989, 13:775.
62. Serruys P W, et al: Evaluation of ketanserin in the prevention of restenosis after PTCA: A muticenter randomized double-blind placebocontrolled trial. Circulation 1993,88:1588-1601.
63. Fuster V, et al: Clinical-pathological correlation of coronary disease progression and regression. Circulation 1992, 86(Suppl Ⅲ): Ⅲ-1-11.
64. Granstrom E: Aspects on measurement of prostaglndins and thromboxanes. Am Clin Biochem 1979,16:6.
65. Sinzinger H, Feigl W, Silberbauer K: Prostacyclin generation in atherosclerotic arteries. Lancet 1979,2:469.
66. Fitzgerald GA, et al: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet-activation. N Engl J Med 1984, 310:1065-81. Gershliek AH: Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? Circulation 1990, 81(Suppl Ⅰ): Ⅰ-28-34.
2. Hjemdahl P, et al: Effects of stress and β-blockade on platelet function. Circulation 1991, 84(Suppl Ⅵ): Ⅵ-44-Ⅵ-61.
3. Mehta J, et al: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3.Role of tachycardia stress and propranolol. Circulation, 1978, 58:881.
4. Hirsh P D, et al: Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J 1982,104:234.
5. Montalescot G, et al: Evaluation of t hromboxane production and complement activation during myocardial ischamia in patients with angina pectoris. Circulation 1991, 84:2054-62.
6. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962,6:927.
7. Diodati J, et al: Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarcton. Am J cardiol 1990,66:683.
8. Moncada S, Vane JR: Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979, 300: 1142.
9. Hamberg M, et al: Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975, 72:299.
10. Viinikka L, et al: Measurement of thromboxane B_2 in human plasma or serum by radioimmunoassay. Prostaglandins 1980,20:759.
11. Patrano C, et al: Low dose aapirin and inhibition of thrombexane B_2 production in healthy subjects. Thromb Res 1980, 17:317-27.12. McGill D, et al: Platelet function and exercise induced myocardial ischemia in coronary heart disease patients. Thromb Res 1989,56: 147.
13. Patrono C: Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990, 81(Suppl Ⅰ): 12-15.
14. Canmeron H A, et al: Platelet size in myocardial infarction. Br Med J 1983,287:449-51.
15. Nerman A G: Platelet activation and aggregation: Rationale for combining antithrombotic drugs. In: Herman AG, ed. Antithrombotics Dordrecht: Kluwer Academic publishers. 1991:1-26.
16．许澍淮：环核苷酸与血小板功能．生理科学进展 1992，23：318．
17. Vaughan DE: Pathophysiology of unstable angina: Other consideration. In: Rutherford JD. ed. Unstable angina. New York: Marcel Dekker.INC. 1992:69-83.
18. Moncada S,et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663.
19. Sors H, et al: Analytical methods for thromboxane B_2 measurement and validation of radioimmunoassay by gas liquid chromatography mass-spectrometry. Prostaglandin. 1978,16:277.
20. Parry M J, et al: Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leucocytes in angina patients and healthy volunteers. Lancet 1982,2:164.
21. Mehta J, et al: Platelet function and biosynthesis of PGI_2 and TXB_2 in whole blood after aspirin administration in human subjects. JACC 1984,4:806-11.
22. Dehmer G J, et al: A new technique for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 1986,12:426.
23. Mehta J, et al: Role Of blood platelet and prostaglandins in coronary artery disease. Am J Cardiol 1981,48:366.
24. Bugiardini R, et al: Evaluation of the effects of catheter sampling??for the study of platelet behavior in the pumonary and coronary. Circulation. Am Heart J 1984,108:255.
25. Nichols A B, et al: Effect of heparin bonding on catheter-induced firin formation and platelet activation. Circulation 1984,70:843.
26. Tate D A, et al: Platelet activation during coronary intervention detected by measurement of platelet-derived microparticles and glycoprotein Ⅱb/Ⅲa expression on platelets in coronary sinus blood. JACC 1993, 21: 77A.
27. Watts SE, et al: Storage of platelets for tests of platelet function: Effects of PH on platelet aggregation and liberation of β-thromboglobulin. Thromb Res 1983,29:343-53.
28. Mehta P, et al: Platelet aggregation across the myocardial vascular bed in man. I.Normal versus diseased coronary arteries. Throm Res 1979, 14:423.
29. Ross R: The pathogenesis of atherosclerosis: An update. N Engl J Med 1986.314:488-499.
30. Dinerman JL. Mehta JL: Endothelial, platelet and leukcyte interactions in ischemic heart disease: Insights into potential mechanism and their clinical relevance. J Am Coll Cardial 1990.16:207-22.
31. Badimon JJ, Fuster V, Chesebro JH et al: Coronary atherosclerosis: A multifactorial disease. Circulatlon. 1993, 87(Suppl Ⅱ): Ⅱ-3-16.
32. Mehta J: Prostaglandin: regulatory role in cardiovascular system and implications in ischemia heart disease. Int J Cardiol 1983,4:246.
33. Fox KAA: Thrombolysis: Adjuvant therapy and the role of complement. Eur Heart J 1990, 11(Suppl F)34-42.
34. Neri Serneri GG, et al: Txb2 production by human arteries and viens Prostaglandins 1983, 25:753.
35. Schror K: Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischemia, Eur Heart J. 1990, 11 (Suppl.B)27-34.
36. Smith E F, Lefer A M, and Nicolau K C: Mechanism of coronary??vasoconstriction by carbocycl ic thromboxane A_2. Am J Physiol. 1981, 240: H493-H497.
37. Mehta J, Nichols W, Mehta P, et al: Thromboxane and prostacyclin in systemic and coronary vascular beds following endoperoxide analogue infusion. Am J Cardiol. 1982,49:1014.
38. Flores N A, Sheridan D J: Platelet mediated alteration in cardiac cellular electrophysiology during normal perfusion and myocardial ischemia. Br Heart J 1991,66:54.
39. Parratt J R and Wainwright C L: Ventricular arrhythmias induced by local injections of vasoconstrictors following coronary artery occlusion. Br J Pharmacol 1986,88:397p.
40. Mehta J, Mehta P, Horalek C:The significance of platelet-vessel wall prostaglandin equilibrium during exercise-induced stress. Am Heart J 1983,105:895.
41. Mehta J, Mehta P et al: Thromboxane release in coronary artery disease: Spontaneous versus pacing-induced angina. Am Heart J 1984,107:286.
42. Cortellaro M, et al: Transcoronary platelat thromboxane A_2 formation without platelet trapping in patients with coronary stenosis—Effect of sulphinpyrozone treatment. Thromb Haemost 1983,50(4):857-859.
43. Tada M, et al: Elevation of thromboxane B_2 levels in patients with classic and variant angina pectoris. Circulation 1981,64:1107.
44. Montalescol G, et al: Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 1991,64:2054-2062.
45. Diodati J G, et al: Platelet activation across the coronary bed in patients with coronary artery disease. J Am Coll Cardiol 1991,17: 321A.
46. Nichols A B, et al: Effect of pacing-induced myocardial ischemia on platelet activation and fibrin formation in the coronary. circulation. J Am Coll Cardiol 1987,10:40-45.
47. Wennmalm A, et al: Excretion of thromboxane A_2 and prostacyclin??metabolites before and after exercise testing in patients with and without signs of ischemic heart disease. Circulation 1990,82: 1737-1743.
48. Fuster V, Badimon L, Badimon J J, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250.
49. Zahavi M, Zahavi J, et al: Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. Thromb and Haemost 1989, 62: 840-845.
50. Theroux P, et al: Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987,75:156-162.
51. Neri Serneri G G, et al: Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina. Thromb Res 1987,46:303-316.
52. Fitzgerald D J, Roy L, Catella C, et al: Platelet activation in unstable coronary disease, N Engl J Med 1986,315:983-9.
53. Meri Serneri G G, et al: Abnormal cardiocoronary thromboxane A_2 production in patients with unstable angina. Am Heart J 1985, 109:732-38.
54. Mikhailidis D J P, et al: Platelet function in patients admitted with diagnosis of myocardiol infarction. Angiology 1987,38:36.
55. Tada M, et al: Augmentod thromboxane A_2 generation and efficacy of its blockade in acute myocardial infarction. Int J cardiol 1985, 8: 301-312.
56. Henriksson P, et al: In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986,55:543-8.
57. Mcdaniel H G, et al: Platelet function abnormalites in response to arachidonic acid in the acute phase of myocardial infarction. Am J cardiol 1983,52:965.
58. Takatsu Y, Yui Y, Hattori R, et al: Platelet aggregation and plasma??thromboxane B_2 in acute myocardial infarction, J moll Cell Cardiol 1985, 17(Suppl 1)1-89.
59. Yamazaki H, et al: Thromboxane A2 synthesizing activity of platelet in coronary artery disease. Jap Cir J 1987,51:451.
60. Takatsu Y et al: Platelet aggregation and thromboxane B_2 release in patients with AMI-Their relation to coronary patency. Jpn Cir J 1988,52:314.
61. Gallino A, et al: Fibrin formation and platelet aggregation in patients with severe coronary artery disease: Relationship with the degree of myocardial ischemia. Circulation 1985,72:27-30.
62. Dalal J J et al: Platelet counts and aggregation in coronary artery disease. Eur Heart J 1982,3:107-113.
63. Robertson RM, et al: Platelet aggrogation in peripheral and coronary sinus blood in patients with spontaneous coronary-artery spasm. Lancet 1980,2:829.
64. Numano F, Aizawa T, Nomura S, et al: Coronary spasma, prostaglandin and and HLA factors. Jap Cir J 1985, 49:119-27.
65. Neri Serneri G G, et al: Reduced prostacyclin production in patiens with different manifestation of ischemia heart disease. Am J Cardiol 1982,49:1146.
66. Fitzgerald GA, et al: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984,310:1065-8.
67. Neri Serneri G G, et al: Impaired cardiac PGI_2 and PGE_2 biosynthesis in patients with angina pectoris. Am Heart J 1986,112:472.
68. Neri Serneri G G, et al: Defective coronary prostaglandin modulation in anginal patients. Am Heart J 1990,120:12.
69. Schror K: Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequences for platelet-vessel wall interactions. In: Herman AGed. Antithrombotics. Dordrecht: Kluwer Academic publishers 1991,139-158.70. Serruys PW, Rutsch W. Heyndrickx G R, et al: Prevention of restenosis after PTCA with thromboxane A_2-receptor biockade. Circulation 1991, 84:1568-1580.
71. Mehta JL, Conti CR: Aspirin in myocardial ischemia: Why, when, and how much? Clin Cardiol 1989,12:179-184.
72. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988,2:349.
73. The Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1988,318:262.
74. Peto R, Gray R, Collins R, et al: A randomised trial of the effects of prophylactic daily aspirin among male British doctors. Br Med J 1988, 296:313.
75. Decaterina R, Giannessi D, Bernini W, et al: Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985,5:589.
76. Altman J D, Dulas D, Pavek T, et al: Effect of aspirin on coronary collateral blood flow. Circulation 1993, 87:583-589.
77. Forman MB, Virmani R, Puett DW: Mechanisms and therapy of myocardial reperfusion injury. Circulation 1990, 81(Suppl Ⅳ): Ⅳ-69-Ⅳ-78.
78. Laws KH et al: Kinetics and imaging of indium-111-labeled platelets in experimental myocardiol infarction. Circulation 1983,67:110.
79. Ruf W, et al: Platelet trapping in myocardial infarct in baboons: Therapeutic effect of aspirin. Am J cardiol 1980,46:405.
80. Tomoda H, et al: Development of experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). Am Heart J 1986,112:696.
81. Austin J, et al:Thromboxane synthetase inhibitor reduces ventricular irrtability after coronary occulusion and reperfusion. Am Heart J 1988,115:505.
82. Grover G J, and Schumacher W: Effect of the thromboxane receptor??antagonist SQ29548 on myocardial infarct size in dogs. J Cardiovasc Pharmacol. 1988,11:29-35.
83. Tsuchida A, Miuka T. Ogawa T, et al: Inhibition of thromboxane A_2 synthetase failed to limit myocardial infarct size in a rabbit ischemia reperfusion model.Jpn Cir J 1991,55:174.
84. Sato N, Endo T, Kiuchi K, et al: Effect of a thromboxane synthetase inhibitor, Y-20811 on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occulusion and reperfusion in dogs. J Cardiovasc pharmacol 1993,21:353-361.
85. Fitzgerald D J, Vright F,FitzGerald G A, et al: Increased thromboxane biosynthesis during coronary thrombolysis: Evidence that platelet activation and thromboxane A_2 modulate the response to tissue-type plaminogen activity in vivo. Cir Res 1989,65:83-94.
86. Rebuzzi AG, Natale A, Bianchi C, et al: Importance of reperfusion on thromboxane A_2 metablite excretion after thrombolysis. Am Heart J 1992.123:560.
87. Schwartz L, Bourassa MG, Lesperance J, et al: Aspirin and dipyridamde in the prevention of restenosis after PTCA. N Engl J Med 1988,318: 1714-19.
88. Ip JH, Fuster V, Iserael D, et al: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J An Coll Cardiol 1991, 17:77B-88B.
89. Badimon L, Badimon JJ, Zuritto VT, et al: Platelet thrombus formation on collagen type Ⅰ: A model of deep vessel injury: Influence of blood rheology, von Willebrand factor and blood coagulation. Circulation 1988, 78:1431-42.
90. Steele PM, Chesebro JH, Stanson AW, et al: Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Cir Res 1985, 57:105-112.
91. Vilentz JR, Sanborn TA, Haudenschild CC, et al: Platelet accumulation in experimental angioplasty: Time course and relation to vascular??injury. Circulation 1987, 75:636-642.
92. Foxon D P, Balelli L A, Sanborn T, et al: The effect of antiplatelet therarpy on platelet accumulation after experimental angioplasty in the rabbit iliac model. Int J Cardiol 1992, 36:41-47.
93. Sassover M A, Abela G S,Koch J M, et al: Angioscopic evaluation of periprocedural and postprocedural abrupt closure after percutaneous coronary angioplasty. Am Heart J 1993,126:444-450.
94. Nobuyoshi M, Kimura T, Ohishi H, et al: Restenosis after PTCA: pathologic observation in 20 patients. J Am Coll Cardiol 1991, 17:433-9.
95. Agrawal SK, Rustagi PK, Quarles LA, et al: Platelet activation during PTCA-is current antithrombotic therapy sufficiently effective? J Am Coll Cardiol 1992 19(Suppl A)108A.
96. Nante S, et al: The effect of percutaneous transluninal coronary angioplasty on syntheses of thromboxane A_2 and prostacyclin in coronary circulation. J Moll Cell Cardiol 1985, 17(Suppl 1)1:90.
97. Peterson MB, et al: THromboxane release during PTCA. Am Heart J 1986,111:1-6.
98. Schwartz L, et al: The role of antiplatelet agents in modifying the extent of restenosis following PTCA: Am Heart J 1990, 119:232.